Larotrectinib(Vitrakvi)

Larotrectinib is the world’s first highly selective neurotrophic tyrosine receptor kinase (TRK) inhibitor and a tissue-agnostic precision targeted antineoplastic agent.

25mg*60capsules
100mg*60capsules

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Larotrectinib Drug News

TRK Inhibitor Vitrakvi Demonstrates Favorable Efficacy in the Treatment of NTRK Fusion-Positive Soli

EMA CHMP Positive Review OpinionRecently, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a po···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 71
Bayer Submits New Drug Application for Vitrakvi (larotrectinib) in Japan for TRK Fusion-Positive Sol

NDA Submission AnnouncementOn May 26, 2020, Bayer announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour ···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 71
FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

FDA Approval AnnouncementNovember 26, 2018 -- The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib).Vit···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 71
U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK

Approval AnnouncementWHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has grant···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 72